Angiotensin Receptor Blockade for ICB-Induced Brain Edema

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunotherapy approaches for glioblastoma, such as immune checkpoint blockers (ICBs), fail to effectively treat the brain edema they induce, which is exacerbated by anti-PD1/PD-L1 antibodies and compromises treatment efficacy due to the immunosuppressive nature of steroids used to manage edema.

Innovation Solution

The use of angiotensin receptor blockers, specifically losartan, to prevent ICB-induced edema by reducing MT-MMP-1 and -2 activity in endothelial cells, thereby reprogramming the tumor microenvironment and enhancing anti-tumor immunity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immunotherapy (ICB) is used to treat glioblastoma, then anti-tumor immunity is enhanced, but brain edema is induced and worsened

Engineering Contradiction:

Improveanti-tumor immunityVSAvoidbrain edema

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces ARBs (angiotensin receptor blockers) as an intermediary substance that mediates between the harmful effect of ICB-induced edema and the beneficial anti-tumor immunity. ARBs block the angiotensin II type 1 receptor pathway to reduce edema without interfering with ICB's immune-enhancing effects, allowing both goals to be achieved simultaneously

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent extracts and addresses the harmful edema component separately from the beneficial anti-tumor immunity effect of ICB. By using ARBs to specifically target and reduce the edema pathway (angiotensin II type 1 receptor signaling), the treatment isolates and removes the harmful effect while preserving the therapeutic benefit

Inventive Principle:

Principle #2Taking out (Extraction)

2Object-affected harmful factors

If corticosteroids are used to control ICB-induced edema, then edema is reduced, but immunosuppression occurs and compromises ICB benefit

Engineering Contradiction:

Improvebrain edemaVSAvoidimmunosuppression

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent replaces expensive, long-term immunosuppressive corticosteroids with a more targeted, temporary ARB intervention. ARBs provide edema control through a different mechanism (angiotensin receptor blockade rather than broad immunosuppression), allowing shorter duration treatment that preserves immune function while still managing edema effectively

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the therapeutic parameter from broad immunosuppression (corticosteroids) to targeted receptor blockade (ARBs). This parameter change shifts the mechanism from suppressing the entire immune system to specifically blocking the angiotensin II type 1 receptor pathway involved in edema formation, thereby maintaining immune competence while controlling edema

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Losartan effectively reduces ICB-induced edema, improving treatment outcomes by normalizing the vasculature and enhancing anti-tumor immunity, with a 20-40% cure rate in combination with standard of care treatments.

Implementation Method 1

the angiotensin receptor blocker (ARB) losartan overcomes ICB-induced edema by reducing endothelial membrane-type matrix metalloproteinase 1 and 2 (MT-MMP-1, -2) activity that is upregulated in response to ICB

Methodology Applied

Scientific EffectMatrix metalloproteinase activity reduction: